Understanding how mutant IDH1 contributes to brain tumor formation and treatment response
Molecular Dynamics of Glioma Formation and DNA Damage Response by Mutant IDH1
This study is looking at a specific change in a gene that’s often found in brain tumors called gliomas, to see how it affects tumor growth and how well these tumors respond to certain treatments, which could help doctors find better ways to help patients with gliomas.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11084561 on NIH RePORTER |
What this research studies
This research investigates the role of a specific mutation in the IDH1 gene, which is commonly found in gliomas, the most prevalent type of primary brain tumor in adults. By creating a genetically engineered mouse model, the study aims to explore how this mutation affects tumor growth and response to treatments, particularly focusing on the sensitivity of these tumors to certain therapies that cause DNA damage. The findings could provide insights into why some patients respond better to treatments than others and help develop more effective strategies for managing gliomas.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with gliomas that have the IDH1 mutation.
Not a fit: Patients with gliomas that do not have the IDH1 mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with IDH1-mutant gliomas.
How similar studies have performed: Previous research has shown promising results with similar approaches in understanding glioma biology and treatment responses, indicating potential for success in this study.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Shi, Diana — Dana-Farber Cancer Inst
- Study coordinator: Shi, Diana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.